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Glucocorticoids are anti-inflammatory drugs that are widely used for the treatment of numerous
(autoimmune) inflammatory diseases. They exert their actions by binding to the glucocorticoid
receptor (GR), a member of the nuclear receptor family of transcription factors. Upon ligand
binding, the GR translocates to the nucleus, where it acts either as a homodimeric transcription
factor that binds glucocorticoid response elements (GREs) in promoter regions of glucocorticoid
(GC)-inducible genes, or as a monomeric protein that cooperates with other transcription factors
to affect transcription. For decades, it has generally beenbelieved that the undesirable side effects
of GC therapy are induced by dimer-mediated transactivation, whereas its beneficial anti-inflam-
matory effects aremainly due to themonomer-mediated transrepressive actions of GR. Therefore,
current research is focused on the development of dissociated compounds that exert only the GR
monomer-dependent actions. However, many recent reports undermine this dogma by clearly
showing that GR dimer-dependent transactivation is essential in the anti-inflammatory activities
ofGR.Manyof these studiesusedGRdim/dimmutantmice,which showreducedGRdimerizationand
hence cannot control inflammation in several disease models. Here, we review the importance of
GR dimers in the anti-inflammatory actions of GCs/GR, and hence we question the central dogma.
We summarize the contribution of various GR dimer-inducible anti-inflammatory genes and ques-
tion the use of selective GR agonists as therapeutic agents. (Endocrinology 154: 993–1007, 2013)
Glucocorticoids (GCs) are critical regulators of a widevariety of fundamental processes, including meta-
bolic homeostasis, cell proliferation, inflammatory and
immune responses, development, and reproduction (1–3).
At pharmacologic concentrations, GCs display potent an-
ti-inflammatory effects. Hence, numerous autoimmune,
inflammatory, and allergic disorders, such as asthma,
rheumatoid arthritis, ulcerative colitis, and allergic rhini-
tis (4, 5), are often treated with synthetic GCs, such as
dexamethasone and prednisolone. Despite their excellent
anti-inflammatory efficacy, the use of GCs as therapeutics
is often restrained due to two major drawbacks. First,
long-term treatment with GCs is often accompanied by
severe side effects, such as diabetes, osteoporosis, hyper-
tension, andmuscle atrophy (6, 7). Second, the occurrence
of GC resistance also limits the success of manyGC-based
therapies.
GCs exert their functions by binding to their intracel-
lular receptor, the glucocorticoid receptor (GR), which is
a ligand-inducible transcription factor belonging to the
nuclear receptor superfamily (8). The GR is a modular
protein composed of three major functional domains: the
N-terminal domain, the central DNA-binding domain
(DBD), and the C-terminal ligand-binding domain (LBD).
The DBD consists of two zinc fingers important for GR
dimerization, nuclear translocation, and DNA binding.
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Each zinc finger contains a zinc atom between four cys-
teine residues. The second zinc finger is more important
for GR dimerization. The DBD and LBD are linked by a
hinge region, which allows nuclear translocation of GR
(9–11) (Figure 1, upper panel).Additionally,GCs can also
bind to another nuclear receptor, the mineralocorticoid
receptor (MR), with a 10-fold higher affinity than with
GR(12), but interferenceofGCs inMRsignaling is limited
due to the topical restriction of MR expression. Whereas
GR is widely expressed, MR is expressed only in certain
types of cells (and regulates salt and water homeostasis).
Furthermore, the action of GCs through theMR is limited
by the activity of 11-hydroxysteroid dehydrogenase 2 in
cells in which MR is expressed (13, 14).
In its inactive state, GR resides predominantly in the
cytoplasm, where it is sequestered in a multimeric chap-
erone complex consisting of heat shock proteins (such as
hsp90, hsp70, hsp90 binding protein p23), immunophi-
lins (eg, FKBP51, FKBP52, Cyp44, and PP5), and other
factors to prevent its degradation and to assist in its mat-
uration (15–17). The GR is constitutively expressed in
virtually all cell types, but the different tissue-specific pat-
terns lead to tissue-specific outcomes in different diseases
(18, 19). Furthermore, GR-mediated effects are readily
influencedby epigenetic regulators, context, andother un-
recognized determinants (20, 21). In addition, the key
variables that determine the GR-mediated outcome in-
clude timing and genomic accessibility of GC-responsive
genes. The nature and magnitude of a cell’s response to
GCs also depend on the levels of hormones secreted by the
adrenal gland in a circadian rhythm
and undergo pulsatile secretion
(22–24).
Although inactive GR is found
primarily in the cytoplasm, it is not
rigidly compartmentalized. GR shuttles
continuouslybetween thenucleus and
the cytoplasm through the nuclear
pore channel (reviewed in Ref. 15).
Nevertheless, upon ligand binding,
GR undergoes conformational changes
and is mainly found in the nucleus
due to its ligand-induced nuclear
translocation. In the nucleus, GR
mediates the up-regulation of nu-
merous genes and down-regulation
of others in a coordinated fashion.
Positive regulation is often mediated
by the binding of GR to GR-binding
sites. The best-described mechanism
of transcriptional activation is thedi-
rect binding of GR homodimers to
so-called GR response elements (GREs) in the promoter
regions of GC-inducible genes (25). In fact, GR ho-
modimers can bind in the major groove of DNA via their
DBD-containing two zinc fingers and thus target a GRE
(5, 26). The consensus GRE sequence is an inverted im-
perfect hexameric palindrome separated by a spacer of 3
bp (5-AGAACAnnnTGTTCT-3, inwhich “n” is any nu-
cleotide) (5, 27). The sequence of the GRE varies among
different promoters, and therefore the GRE can be con-
sidered as a sequence-specific allosteric ligand directing
the transcriptional activity of GR (28, 29). However, re-
cent global ChIP-Seq data reveal that GR binds to DNA
mostly via the GRE consensus motif (30). Additionally,
next to transactivation (TA) of “simple” GRE motifs by
GR dimers, GR can cooperate with other transcription
factors as a monomeric protein to induce transcription
(31, 32) to so-called “composite” elements or by a “teth-
ering” mechanism. Binding of GR to DNA leads to re-
cruitment of distinct cofactors that enable chromatin re-
modeling, RNA polymerase II binding, and subsequent
gene induction. The mechanisms of GR-mediated tran-
scriptional repression or transrepression (TR), on the
other hand, are more promiscuous and partly involve
DNA binding of homodimeric GR to simple negative
GREs (nGREs)or inverted repeats (IR)with less than three
spacers to specifically repress gene transcription (33–35).
Furthermore, GC-activated monomeric GR can nega-
tively regulate gene transcription, eg, by tethering other
transcription factors, such as nuclear factor-B (NF-B)
and activator protein 1 (AP-1), or through cross-talk with
Figure 1. General Structure of the GR GR (human) is composed of an N-terminal domain (NTD),
a DBD, a hinge region, and a C-terminal LBD. The GR DBD contains two zinc fingers in which the
zinc molecule is located between four cysteine residues. In GRdim/dim mice A458 (red) is mutated
to a threonine. The mutant GR cannot form dimers.
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other transcription factors and binding to “composite”
elements (36, 37). For an overview of the fundamental
aspects of GR transcriptional regulation, see Figure 2.
The anti-inflammatory effects of GR are believed to
generally result from tethering protein-protein interac-
tions between GR and other transcription factors, partic-
ularly NF-B and AP-1, which results in TR of a wide
variety of proinflammatory genes. On the other hand, the
debilitating GC-mediated effects are thought to be caused
by TA of simple GRE genes (38, 39). Accordingly, so-
called selectiveGR agonists (SEGRAs) that favor TRwere
developed as therapeutic agents with reduced side effects.
Examples are RU24858, compound A, AL-438, LGD5552,
and ZK 216348 (40–45). However, more recent data
show that the TA potential of GR is indispensable for its
anti-inflammatory properties, at least in certain disease
settings. Here, we provide an overview of the anti-inflam-
matory mechanisms of GR, focusing mainly on the induc-
tion of anti-inflammatory genes by GR as a homodimeric
transcription factor and with emphasis on in vivo studies.
Current Concept of the
Anti-inflammatory
Mechanism of GC/GR:
Emphasis on TR
Until recently, it was generally be-
lieved that TR of transcription fac-
tors by monomeric GR is the main
determinant of the anti-inflamma-
tory properties of GR, whereas its
side effects reside in its TA potential
(36, 38, 39, 46). This concept has
been reviewed extensively (31, 41,
47). Briefly, it is known that TA,
through direct DNA binding, in-
duces the expression of several en-
zymes (eg, phosphoenol pyruvate
carboxykinase, tyrosine aminotransfer-
ase, andglucose6-phosphate) involved
in glucose and lipid metabolism.
Hence, uncontrolled up-regulation
of these genes could account for the
diabetogenic effects of GCs, which
result in hyperglycemia and de-
creased carbohydrate tolerance (1,
48). On the other hand, it is believed
that the anti-inflammatory actions
of GC therapy are predominantly re-
lated to the TR effects ofGR (11, 49)
because some inflammatory pro-
cesses could still be restricted in a
mouse strain (GRdim/dim) in which GR is largely dimeriza-
tion defective due to replacement of an alanine by a thre-
onine (A458T) (11, 50, 51). Thismutation is located in the
second zinc finger in the DBD of GR (Figure 1, lower
panel) and causes reduced binding to DNA and, more
specifically, to the GRE (11, 50, 51).
TR of inflammatory target genes most often involves
interference of GR with the activity of DNA-bound pro-
inflammatory transcription factors, such asNF-B, cAMP
response element-binding protein, interferon regulating
factor-3, nuclear factor of activated T cells, signal trans-
ducers and activators of transcription, Th1-specific T box
transcription factor, GATA3, and AP-1 (52–54). Because
these transcription factors regulate the expression of in-
flammatory genes, GR-mediated tethering of these tran-
scription factors eventually leads to repression of a large
numberof proinflammatorymediators: cytokines (includ-
ingTNF, granulocytemacrophage colony stimulating fac-
tor, IL-1, IL-2, IL-3, and IL-6), chemokines (eg, eotaxin,
macrophage inflammatory protein [MIP], and regulated
and normal T cell expressed and secreted [RANTES]), en-
Figure 2. GR Signaling Activated GR can lead to either activation or repression of gene
transcription. Left green panel: TA is mediated by (i) binding of GR dimers to GRE, (ii) DNA
binding of GR in concert with another transcription factor (TF: XY), or (iii) binding of GR to a TF
by a tethering mechanism. Right red panel: TR is mainly achieved by (iv) direct binding of GR
dimers to nGRE (simple or IR), (v) DNA-binding cross-talk with another TF, (vi) interference of
monomeric GR with the TA activity of TFs by a tethering mechanism, (vii) competition for an
overlapping binding site (competitive GRE), (viii) sequestration of a DNA-bound TF, or (ix)
competition for binding cofactors with other DNA-bound TFs.
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zymes (such as inducible nitric oxide synthase and cyclo-
oxygenase 2 [COX2]), and adhesion molecules (eg, inter-
cellular adhesion molecule 1 and vascular cell adhesion
molecule 1). Thus, negative regulation by tethering has
become a paradigm for the anti-inflammatory and im-
mune-suppressive actions of GR. The most-studied cross-
talk mechanisms are those between GR and NF-B, GR
and AP-1, and GR and interferon regulating factor-3 (41,
42, 45, 55).
Studies on GRdim/dim Mice: The Emerging
Role of GR Dimerization in the
Anti-inflammatory Function of GR
Asmentionedabove,most studies claim that interactionof
monomeric GR with proinflammatory transcription fac-
tors is the basis of its anti-inflammatory activity. How-
ever, the contribution of GR dimers to its anti-inflamma-
tory property remains controversial. Mounting evidence
indicates that theTApotential ofGRdimers is required for
execution of the complete anti-inflammatory cascade (49,
56–59). Most studies involved experiments in GRdim/dim
mice.
Importantly, GRE-dependent gene transcription is di-
minished in cells originating from GRdim/dim mice, as
shownby impaired inductionof amousemammary tumor
virus-CAT reporter inGRdim/dimmouse embryo fibroblast
cells and GR-inducible gluconeogenic enzymes, such as
g6p and pck1, in liver lysates of GRdim/dim mice and re-
duced (but not absent) GC regulation of genes in the liver
as revealed by genome-wide expression profiling (10, 11).
However, the repressing function (cross-talk with AP-1
andNF-B) of GR is still intact in GRdim/dim mice (11, 49,
51, 60).
Almost all evidence discussed in this review is based on
the analysis of the single-point mutant A458T, otherwise
known as the GRdim/dim mutant. However, one should
consider these data with caution, because mounting evi-
dence indicates that additional residues are indispensable
for GR dimerization. The idea that GRdim/dim mutants
cannot form dimers has been challenged by a recent study
(61). Human osteosarcoma (U-2 OS) cells expressing the
GRwt/wt receptor or the hGRdim/dim (A458T) or hGRdim4
(A458T, R460D, D462C, andN454D) mutant were used
with GRE-driven reporters in transient reporter gene as-
says. The results revealed that the hGRdim4 mutant is even
more unresponsive to steroids than the hGRdim/dim
(A458T)mutant. These findings are in agreementwith the
resistance of human cell lines carrying these mutations to
GC-mediated apoptosis (61). These findings are in line
with earlier published data showing that both the GRdim/dim
andGRdim4mutations in theD-loop strongly inhibitedGR
dimerizationandGR-mediatedTAbutdidnot hamper the
repression of AP-1 and NF-B (51). Indeed, Jewell et al.
(61) also showed that the TR capacity of hGRdim/dim was
indeed unaffected. What is particularly interesting is that
immunoprecipitation experiments showed that both
the human (h)GRdim/dim and hGRdim4 receptors could
promptly form dimers. Of course, these striking findings
should be experimentally confirmed further. Further-
more, Savory et al. (62) have demonstrated a novel dimer
interface in theLBDofGR.Mutating thisdimer interface’s
most important residues (P625 and I628) to alanines re-
sulted in a 10-fold decrease in dimerization affinity rela-
tive to wild-type (WT) LBD. Furthermore, by using a
mousemammary tumor virus reporter assay, Bledsoe et al.
(63) showed that the residues of this dimer interface are
also important for theGRTA function,. In addition,more
recent gene expression profiling by Frijters (10 unambig-
uously confirms that the GRdim/dim mutant can still trans-
activate some genes, albeit not as strongly as its wild type
counterpart.
Taken together, all the above-mentioned findings indi-
cate that the single-point mutation in the DBD, namely
A458T in the GRdim/dim mutant, may not be sufficient to
completely abolish dimerization and thus GR-mediated
TA.Most probably, theGRdim/dimmutant can still bind to
a set of GR-responsive promoters, although in a cell type-
and gene promoter-specific manner, by forming multim-
ers independently of the DBD-dimer interface. Neverthe-
less, all studies performed with the GRdim/dim mutant and
subsequent findings do prove that this single-point muta-
tion reduces dimerization, and that the GR-DNA binding
potential and TA are critically important in the anti-in-
flammatory actions of GR.
Mice carrying theGRdim/dimmutation (11) areviable, in
contrast to the full GR knock-out mouse (64). GRdim/dim
mice are normal in size and appear normal, but they do
show some anomalies, such as increased expression of
Pomc in the pituitary gland, which demonstrates the loss
of negative control of Pomc transcription by GR dimers.
This results in elevated levels of secreted ACTH and GCs
(11, 65). Additionally, studies on GRdim/dim mice revealed
that GR dimerization is required for GC-mediated thy-
mocyte apoptosis and long-term proliferation of erythro-
blasts (11). Another cellular process that necessitates ac-
tion of GR dimers is adipogenesis: this process could be
promoted by induction of Krüppel-like factor 15 by a
dimerized GR (66). Furthermore, GR dimers are also re-
quired for the task-related facilitating effects of GCs on
spatial memory (65). In contrast, dimerization of GR is
dispensable for epidermal and hair follicle development
during embryogenesis (67).
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The contribution of the DNA-binding function of GR
to the anti-inflammatory effects of GR was until recently
strongly underestimated. Several studies have exploited
the response of GRdim/dim mice in several inflammatory
disease models (Table 1). It has been shown that DNA-
binding GR dimers are not required in GC therapy of
irritative skin inflammation induced by phorbol ester
(phorbol myristate acetate), and that GR monomers can
inhibit inflammation in this model (49, 60). In contrast,
GRdim/dim mice were refractory to GC treatment in a
mouse model of contact hypersensitivity, which mimics
allergic contact dermatitis (58). These data indicate that
dimerization ofGR and subsequentGRE-dependent tran-
scription are indispensable for the restriction of certain
allergic inflammatory disorders. Similar to contact hyper-
sensitivity, Baschant et al. (56) showed that GCs require
GR dimer activity to restrain inflammation in twomurine
rheumatoid arthritis models: antigen-induced arthritis
(AIA) and glucose-6-phosphate isomerase-induced arthri-
tis. GC treatment did not protect GRdim/dim mice, indicat-
ing that the DNA-binding capacity of dimeric GR is
required for GC-mediated suppression of arthritis inflam-
mation.Moreover, GRdim/dim mice are also highly suscep-
tible in several septic shockmodels, such as sepsis induced
by lipopolysaccharide (LPS) or cecal ligation and punc-
ture, and inflammation induced by TNF (57, 59). These
studies provide evidence that in septic shock, the thera-
peutic actions of endogenous and exogenous applied GCs
require GR dimerization. Taken together, these data un-
dermine the concept that GR monomers are responsible
for most of the anti-inflammatory potential of GCs and
clearly show that GR dimer-dependent TA is essential for
the anti-inflammatory activities of GR.
GR Dimer-Dependent Transcriptional
Actions
GR-mediated TA of anti-inflammatory genes
Gene expression profiling of livers of GRwt/wt and
GRdim/dim mice treated with prednisolone revealed that
many genes could not be significantly induced in GRdim/dim
mice, indicating that their induction depends on GR
dimers (10). Many of these genes have well-known anti-
inflammatory actions and, hence, might contribute to the
anti-inflammatory properties of GR. Here, we will focus
on a few prominent genes and elaborate on their anti-
inflammatory actions. A complete overview of all GC-
inducible anti-inflammatory genes identified so far and
their effects on the proinflammatory cascade are depicted
in Table 2 and Figure 3.
Whereas Dusp1, Tsc22d3, and Anxa1 are only just a
few GC-inducible genes mediating some of the anti-in-
flammatory capacities of GR, microarray profiling data
indicate that many other genes are positively regulated by
GR and play a putative role in the dispute against inflam-
mation (10, 57, 68). However, identification of these
genes and their functionality is still in its infancy, which
means that the complexity of the anti-inflammatory na-
ture of GR is still far from fully understood.
MAPKphosphatase 1 or dual specificity phosphatase
1 (MKP-1 or Dusp1)
Dual specificity phosphatase 1 (encoded by Dusp1) is
one of the most potent anti-inflammatory GR-inducible
proteins. It is a member of the dual-specificity phospha-
tases, which include 10 members, and catalyzes the de-
phosphorylation and subsequent inactivation of both
Table 1. Identification of the role of GR dimers in different physiological responses to GCs by using GRdim/dim mice
Effects GR Dimerization Important Cell Types References
Resolution of inflammation
Antigen- and G6PI-induced arthritis Required IL-17 producing T-cells (56)
Contact hypersensititivity Required Macrophages Neutrophils (58)
LPS- and CLP-induced septic shock Required Macrophages (57)
PMA-induced irritative skin inflammation Dispensable T-lymphocytes Macrophages (49, 60)
TNF-induced inflammation Required Intestinal epithelial cells (59)
Side effects
Hyperglycemia Required Enterocytes (124)
Osteoporosis Dispensable Osteoblasts Osteoclasts (85, 125)
Skeletal muscle atrophy Dispensable Unknown (126)
Wound repair Required Unknown (123)
Cellular processes
Adipogenesis Required Fibroblasts (66)
Apoptosis Required Thymocytes (11, 61)
Epidermal development during embryogenesis Dispensable Unknown (67)
Proliferation Required Erythroblasts (11)
Spatial memory Required Unknown (65)
CLP, cecal ligation and puncture; PMA, phorbol myristate acetate.
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threonine and tyrosine residues in MAPKs, hence the
name MAPK phosphatases (MKPs) (69, 70). There are
three well-defined MAPK subfamilies: the ERKs, c-Jun
N-terminal or stress-activated protein kinases (c-jun N-
terminal kinase [JNK] or stress-activated protein kinase),
and p38MAPK. These kinases play an intricate role in the
host-immune response leading to the activation of proin-
flammatory transcription factors, such as NF-B and
AP-1, and ensuing activation of various cytokines, chemo-
kines, and inflammatory mediators. MKP-1 was origi-
nally identified as a phosphatase specific for ERKMAPKs
(71, 72). However, consecutive studies have shown that
Table 2. List of GC-Induced Anti-inflammatory Genes
Symbol Description Anti-inflammatory Mechanism References
ADORA3 Adenosine A3 receptor Inhibition of eosinophil chemotaxis (68)
ADRB1 2-Adrenergic receptor 1 Suppression of JNK signaling, suppression of cytokine secretion (128)
ANPEP Aminopeptidase N Cleaves antigen peptides bound to major histocompatibility
complex class II molecules of presenting cells
(129)
ANXA1 Annexin-1 Inhibition of phospholipase 2 (cPLA2), COX-2 and NF-B (99–103)
ASBT/SLC10a2 Apical sodium-dependent bile
acid transporter
Bile acid transporter (130–132)
CC10 Clara cell 10 kDa Inhibition of phospholipase 2 (cPLA2); binds hydrophobic
ligands, eg, phospholipids and prostaglandins; inhibits
chemotaxis and phagocytosis of neutrophils and monocytes
(133–139)
CD163 Hemoglobin scavenger
receptor
Clearance of proinflammatory hemoglobin-haptoglobin
complexes
(68, 140–143)
CD1d Antigen-presenting
glycoprotein
MHCI-mediated immunosuppression (stimulates inhibitory NK
and invariant T-cells)
(68)
CYP1A2 Thymosin and 4 sulfoxide Inhibits neutrophil chemotaxis (144)
DEXRAS1/AGS-1 RAS, dexamethasone-induced
1
Inhibits ligand-dependent signaling by the Gi-coupled FPR and
subsequently ERK-1/2 activation; blocks PKC kinase activity
(145–148)
DOK-1 Docking protein 1 Inhibitory adaptor protein (suppresses activation of MAPK
cascade)
(149)
DUSP1/ MKP-1 Dual specificity phosphatase 1 Inhibits MAPKs (JNK/p38/ERK) (59, 71–75)
FCAR Receptor for Fc fragment of
IgA
Interacts with IgA-opsonized targets (68)
FOXP3 Forkhead box P3 Suppression of Treg cells (150, 151)
FPR Formyl peptide receptor Suppression of cytokine secretion (68)
IL-10 IL-10 Suppression of Treg cells, inhibits expression of
proinflammatory cytokines, inhibits NF-B activation
(68, 152, 153)
IL-1r2 IL-1 receptor type II Decoy receptor for IL-1 receptor (154, 155)
IL-1ra IL-1 receptor antagonist Competitive inhibition of IL-1b binding to its receptor (156)
IB Inhibitor of NF-B Inhibition of NF-B (46, 50, 157,
158)
KLF2 Kruppel-like factor 2 Inhibition of NF- B and AP-1 (159)
LILRB1 Leukocyte immunoglobulin-
like receptor, subfamily B
member 1
MHCI-mediated immunosuppression (68)
MT1X Methallothionein 1X Free radical scavenger (160)
p11/ S100A10 S100 calcium binding protein
A10
Inhibition of phospholipase 2 (cPLA2) (161, 162)
p57Kip2 Cyclin-dependent kinase
inhibitor 1C
Cyclin-dependent kinase inhibitor (163)
PAI-1 Plasminogen activator
inhibitor 1
Inhibition of the fibrinolytic cascade (160)
RGS-2 Regulator of G-protein
signaling 2
Reduces Gq-linked signaling (160)
SLAP Src-like-adaptor protein Reduces T-cell signaling by interacting with Syk/Zap70 (164)
SLPI Secretory leukocyte peptidase
inhibitor
Inhibitor of serine proteases (165)
TSC22D3/GILZ TSC22 domain family,
member 3
Inhibition of NF-B, AP-1, Raf-1 and Ras (82–84, 86–
90)
TTP Tristetraprolin Destabilizes mRNA and increases mRNA turnover (137,
166–171)
PKC, protein kinase C.
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MKP-1 has a preference for JNK and p38 MAPKs (73–
75). The interaction of MKP-1 with its substrates, the
MAPKs, increases its activity up to 6- to 8-fold (76). The
regulation ofMkp1 is of much interest but remains contro-
versial. Recently,ChIP sequencing revealed aGRE site in the
promoter region ofMkp1 (77, 78).Moreover, it was shown
that the GC-mediated induction of Mkp1 is dependent on
GR dimerization when cells and tissues are exposed to GCs
aloneor in combinationwithTNF (10, 59),whereasMKP-1
protein is similarly induced in GC-pretreated cells followed
byLPS induction (79).Mkp1 is expressed in response toGCs
in a wide variety of tissues, but it can also be induced by
several proinflammatory stimuli, suggesting that MKP-1
functions as a negative feedback regulator ofMAPK signal-
ing and is consequently critical for the resolution of inflam-
mation.MKP-1was also suggested tomediate the protective
role of endogenous GCs by interfering with p38 signaling
during LPS-induced septic shock (80). Knowledge of the im-
portance ofMKP-1 in the combat against inflammationwas
gainedfromstudiesonMkp1/mice(foranoverviewof the
useofMkp1/mice inproinflammatorydiseasemodels see
Table 3).Additionally, an increasing number of in vivo stud-
ies making use ofMkp1/ mice demonstrate that MKP-1
contributes to the anti-inflammatory responses of GCs. For
example,GCs canprotectMkp1/miceonlypartly against
endotoxic shock (81)andTNF-induced inflammatory shock
(59).Mechanistically,MKP-1protectsagainstTNF-induced
lethal shock by dephosphorylating JNK, more specifically
JNK-2 (59). Furthermore, it was shown that dimerization of
GR is essential for protection against acute TNF-mediated
inflammation and critical for Mkp1 induction and
hence controls activation of the proapoptotic JNK-2. In
this respect, this study was the first to prove that GR
dimerization is also important in the regulation of TNF-
induced apoptosis (59).
These findings together show unambiguously that
MKP-1 has a pivotal role as a negative feedback regu-
lator of the MAPK-signaling cascade and hence is im-
portant in proinflammatory cytokine production and
innate immunity.
Figure 3. An Overview of All Known GC-Inducible Anti-inflammatory Genes and Their Effects on the Proinflammatory Cascade. GR can resolve
inflammation by (i) hampering the activation of proinflammatory signaling pathways through induction of IL-1 receptor antagonist (IL-1ra), IL-1r
type II (IL-1r2), secretory leukocyte peptidase inhibitor (Slpi), thymosin 4 sulfoxide, adenosine A3 receptor (ADORA) and aminopeptidase N
(ANPEP); (ii) interfering with signaling cascades through Dok-1, SLAP, Dexras-1, RGS-2, Gilz and p57Kip2; (iii) inhibition of subsequent MAPK
activation via Gilz, MKP-1, p57Kip2 and B2 adrenoceptor; (iv) interacting of Gilz, IB, Annexin-1, KLF2 and IL-10 with proinflammatory
transcription factors; (v) inducing mRNA destabilization through TTP; (vi) inhibiting protein function via induction of Annexin-1, Cc10, IL-10, p11,
p57Kip2, FPR, CD1d, LILRB1, Foxp3 and MT1X; (vii) negatively regulating various processes through ANPEP, PAI-1, Foxp3, B2 adrenoceptor, Cc10,
ASBT, LILRB1, FCAR and CD163.
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GC-induced leucine zipper (GILZ)
Tsc22d3 (encoding GC-induced leucine zipper or
GILZ) is considered aprototypeof aGC-inducedgene and
is therefore often represented as amere readout product of
the GC-induced signaling cascade. However, it also me-
diates the effects of GCs in immune function. GILZ be-
longs to the family of TGF--stimulated clone 22 domain
(TSC22D) proteins. This family includes genes transcrip-
tionally activated by TGF- and GCs in a wide variety of
cell lines and tissues (82–84). Tsc22d3 induction by GCs
is inhibited in GRdim/dim mice ( Ref. 85; our unpublished
results). Moreover, the Tsc22d3 promoter region dis-
plays six putative GRE motifs, as well as motifs for
other transcription factors. The GILZ protein has been
reported to bind to Ras and Raf-1 and the downstream
proinflammatory transcription factors NF-B andAP-1
(86, 87). Ras is a membrane-associated protein activat-
ing a number of signaling cascades, including the RAF-
MEK-ERKand phosphatidylinositol-3 kinase-AKTpath-
ways (88–90). Furthermore, by binding to Raf-1, GILZ
inhibits MEK and ERK phosphorylation and subsequent
activation. In this way, GILZ induction seems to be one of
the mechanisms by which GCs regulate the MAPK-sig-
naling cascade, albeit indirectly.Next,GILZhas also been
shown to interact with p65 (subunit of NF-B) and both
c-Fos and c-Jun (subunits of AP-1) (86, 91). These anti-
inflammatory properties of GILZ indicate an immune
modulatory role. The anti-inflammatory actions of GILZ
have been confirmed by using mouse models of chronic
inflammatory diseases, such as dinitrobenzene sulfonic
acid (DNBS)-induced colitis (a model of inflammatory
bowel disease) (92), collagen-induced arthritis (CIA) (a
murinemodel of RA) (93), and experimental autoimmune
encephalomyelitis (a model of multiple sclerosis [(MS])
(94). The use of GILZ-overexpressing transgenic mice
demonstrated that GILZ can antagonize the development
Table 3. Use of Mkp1/ Mice in Several Disease Models
Inflammatory Disease Model
Anti-inflammatory
Mechanism Outcome References
Anaphylaxis Inhibition of p38 Enhanced mast cell degranulation; increased
hypothermia
(172)
Colitis Inhibition of MAPK Severe colitis, mucosal hyperplasia (173))
Diet-induced obesity Inhibition of JNK Resistant (174)
Experimental autoimmune
encephalomyelitis (EAE)
Deficiency in CD4 T
cells role for JNK?
Resistant (175)
Experimental induction of arthritis
(EIA)
Inhibition of p38 Increased cytokine levels; increased joint-
swelling; inflammation in ankle and wrist
joints
(176)
Experimental periodontitis Inhibition of p38 Inflammatory bone loss (177)
Hypoxia3 pulmonary hypertension Inhibition of p38 Lower levels of eNOS and lower NO
production; increased levels of arginase I/II
(178)
Infection with gram-negative
bacteria3 sepsis
Inhibition of p38 and JNK Impaired bacterial clearance; increased
cytokine levels; infiltration of neutrophils
in lungs; increased mortality
(179)
Infection with gram-positive bacteria Inhibition of p38 and JNK Increased cytokine and chemokine levels;
greater NO production; neutrophil
infiltration; severe organ damage; higher
mortality
(180)
Influenza viral infection Defective CD4/CD8 T
cell responses  role
for JNK?
Increased weight loss; impaired viral
clearance
(175)
Ischemia-reperfusion injury Inhibition of p38 Greater infarct injury (181)
LPS-induced endotoxemia and septic
shock
Inhibition of p38 and JNK Increased cytokine levels; hypotension;
respiratory failure; increased NO
production; MOF; increased mortality
(81, 176,
182–
184)
Polymicrobial peritonitis (Casp and
CLP)
No mechanism described Increased cytokine and chemokine levels;
increased lethality
(185)
Stress Inhibition of p38 and JNK (184, 186)
TNF-induced acute inflammation Inhibition of JNK-2 Increased cytokine and chemokine levels;
enhanced intestinal damage; increased
mortality; cell death
(59)
Zymosan-induced inflammation Inhibition of p38 and JNK No response to Dex in terms of leukocyte
infiltration and cytokine suppression
(79)
CLP, cecal ligation and puncture; Dex, dexamethasone; eNOS, endothelial NOS; MOF, multiple organ failure.
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of colonic inflammation induced by DNBS (92). In addi-
tion, in vivo delivery ofTsc22d3 small interfering RNA in
CIA mice increased disease severity, indicating that GILZ
has an important protective function (93). Moreover, in
vitro, GILZ small interfering RNA inhibited the suppres-
sion of LPS-induced cytokines by GCs (95). Furthermore,
GILZadministration had amore protective effect than the
administration of high doses of GCs in both DNBS-in-
duced colitis and CIA. In addition, the anti-inflammatory
actions of GCs (up-regulation of GILZ upon GC treat-
ment has also proven effective) in patients suffering from
alcoholic hepatitis (AH) are dependent on Gilz (96). In
summary, these data show that GILZ is a key mediator of
the anti-inflammatory properties of GCs.
Annexin-1
Annexin-1 or lipocortin-1 (encoded by AnxA1) is a
member of the annexin superfamily of calcium- and phos-
pholipid-binding proteins (97). The human AnxA1 pro-
moter region contains a GRE element, but whether it can
be induced in GRdim/dim mice has not been reported (98).
Annexin-1 was originally described as a GC-induced pro-
tein inhibiting the activity of phospholipase A2, which is
known to cleave arachidonyl-containing phosphatides in
the cell (99, 100). Arachidonic acid can be further modi-
fied by cyclooxygenases (COX) to yield the proinflamma-
tory mediators prostaglandins and leukotrienes. An-
nexin-1 also inhibitsNF-B, by binding to the p65 subunit
and thereby prevents its binding to DNA and to COX-2
(101–103). Neutralizing antibodies against annexin-1 ab-
rogated the inhibitory action of GCs in the rat hind paw
carrageenan edema model and in a rat ischemia-reperfu-
sion injury model (104). Studies on AnxA-1/ mice
showed that annexin-1 is protective in AIA, bleomycin-
induced lung fibrosis, and dextran sodium sulfate -in-
duced colitis: the diseases were more severe inAnxA-1/
mice (105–107). It has also been suggested that annexin-1
is protective in CIA, ulcerative colitis, and chronic gran-
ulomatous inflammation (102, 108, 109).Moreover,GCs
exerted no inhibitory effects in Anxa-1/ mice in a car-
rageenan- or zymosan-induced inflammatory model or in
AIA, suggesting that annexin-1 mediates anti-inflamma-
tory actions ofGCs (107, 110).Annexin-1was also shown
to modulate the repair of gastric mucosal injury, because
treatment with an annexin-1 mimetic significantly en-
hanced gastric ulcer healing (111) and the use of an an-
nexin-1-based peptide, MC-12, resulted in amelioration
of symptoms in both dextran sodium sulfate and 2,4,6-
trinitrobenzene sulfonic acid-induced colitis models in
mice (112). In summary, these findings raise interest in
annexin-1 as a GC-inducible effector of inflammation
resolution.
GR-mediated TR of nGRE genes
Figure 2 explains how GR dimers are also required for
TR of nGRE genes (33, 34). These so-called nGRE ele-
ments, comparable to normal GRE, are composed of two
inverted repeats (hexanucleotides) that are either adjacent
or separated by one or 2 bp (CTCC(n)0–2GGAGA; re-
ferred to as IR0, IR1and IR2, respectively) (35).However,
the anti-inflammatory capacity of GR-mediated TR of
nGRE genes is unknown. Nevertheless, a recent study by
Surjit et al. (35) indicated that TR of nGRE genes by GR
dimers can transcriptionally repress the expression of the
cytokine thymic stromal lymphopoietin through direct
binding of dimeric GR to a nGRE. This mechanism could
account for the GR-mediated restriction of atopic derma-
titis. These findings suggest that the sensitivity of GRdim/dim
mice in several diseasemodels can alsobe accounted for by
reduced TR of nGRE genes. It was reported that nGREs
are present in more than 1000 mouse/human ortholog
genes, some of which are known to encode proinflamma-
tory mediators, which indicates the importance of this
mechanism as an additional level of anti-inflammatory
GR signaling (35). The contribution of nGRE genes to the
anti-inflammatory cascade of GR remains to be eluci-
dated, but nevertheless poses an interesting field of inves-
tigation. Thorough investigation, for example by studying
the expression profiles of these genes in GRdim/dim mice,
could leadtothe identificationofnewanti-inflammatoryGR
targets.
GC-mediated proinflammatory effects
The above-mentioned studies demonstrate the strong
anti-inflammatory actions of GCs. However, GCs are not
exclusively immunosuppressive (113); GCs also assist in
maintaining and even facilitating immunity. For example,
adrenalectomized mice and patients with Addison’s dis-
ease produce no GCs, and both of these are more suscep-
tible to infection (114). Indeed, it has been reported that
GCscanhave enhancingeffectson immunecells (115). For
example, it has been reported that depending on the com-
position of the GR-AP-1 dimer, GR can influence the ac-
tivity AP-1 either positively or negatively (116). Also, dis-
ruption of GC action in osteoblasts resulted in a more
rapid resolution of inflammation in the K/BxN model of
experimental arthritis, suggesting that GCs have a proin-
flammatory role in this model (117). Moreover, in addi-
tion to their immunosuppressive effect on TLR signaling,
GCs also affect TLR expression. For instance, the pro-
moter of TLR2 is cooperatively stimulated by GCs and
TNF, through the presence of a functional NF-B site, a
GRE element, and a signal transducers and activators of
transcription-binding element (118). Generally, GCs are
immune stimulatory within the normal physiologic range
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of hypothalamic-pituitary-adrenal axis activity and inhib-
itory when GC levels are higher, as in chronically stressed
animals. These findings clearly indicate the effects of GCs
are critically dose dependent: supraphysiologic doses of
GCsmost probably result in thewidelyGC-mediated anti-
inflammatory effects, whereas lower doses can be
immunomodulatory.
Conclusion and Future Perspectives
In this review we emphasize the importance of GR
dimerization in the combat against, or resolution of, in-
flammation. It is generally believed that the anti-inflam-
matory aspect of GR results from TR of proinflammatory
genes by the tethering of monomeric GR to other tran-
scription factors. However, some recent studies using
GRdim/dim mutant mice indicate that GR dimers also ac-
count for the resolutionof inflammationbyGR.Thephys-
iology of GR, ie, its isoforms, posttranslational modifica-
tions, the recruitment of cofactors, and its subsequent
actions are strongly tissue specific.Moreover, there is sub-
stantial temporal variation in GC-mediated actions, and
this is reflected in time-dependent gene-specific induction.
This might explain the discordant reports on the response
of GRdim/dim mice in distinct inflammatory environments
(Table 1). It isworthwhile to decipher the tissue- and time-
specific effects of GCs because it could resolve the con-
tradictions in the reported results and clarify the role of
GR actions in several diseases.
Interestingly, the continuing identification of new
GRE-dependent genes with anti-inflammatory properties
demonstrates that the TA potential of GR is indispensable
and indicates that the mechanism of the anti-inflamma-
tory action of GR is far from completely understood, in-
cluding the unidentified role of nGRE-dependent genes.
In-depth knowledge of these mechanisms will elucidate
whether GR dimerization preventing GR ligands are, in
fact, potential therapeutics in the combat against inflam-
mation or might be dangerous rather than helpful in this
aspect. Indeed, many scientists have tried to develop
SEGRAs that preferentially induce the formation of
monomers (33, 35, 42, 119–121). However, only two
compounds have made it to clinical trials for topical ap-
plication. This is probably due to the fact that an increas-
ing amount of data is being published on the importance
of GR dimers in the resolution of inflammation. Further-
more, the above-mentioned dogma is challenged by data
showing that GRdim/dim mice still suffer from some side
effects uponGC treatment (122),whichmeans that not all
side effects can be explained by reduced GR TA activity.
Although it was demonstrated that GR dimers play an
intricate role in the development of hyperglycemia and
wound repair (123, 124), GC therapy in GRdim/dim mice
still reduces bone formation and attenuates osteoblast dif-
ferentiation, both of which are characteristics of GC-in-
duced osteoporosis (85, 123–125). Next, GRdim/dim mice
andGRwt/wtmice show the same degree ofmuscle atrophy
upon GC therapy, suggesting that monomeric GR is suf-
ficient to cause skeletal muscle atrophy (126). This could
bebecausenot all genes that arepositively regulatedbyGR
are affected by the GRdim/dim mutation, such as genes de-
pendent on composite elements or tethering mechanisms
(Figure 2). It must be noted that it is difficult to differen-
tiate between TA andTRbecause theGR coactivator GR-
interacting protein 1 is also recruited to sites of GR re-
pression, indicating that it also has a corepressor function
(20). These findings indicate that GR-interacting protein
1 has a dual function: facilitating both TA and TR aspects
of GR action depending on the genomic context. This in-
dicates that dissociating compoundswill likely still induce
certain unwanted side effects. In addition, SEGRAsmight
not activate all the mechanisms of TR actions. For exam-
ple, compound A effectively blocks NF-B, but not AP-1
(Ref. 127 and our unpublished data). Moreover, an
emerging role for GR-dimer-mediated TR of nGRE genes
also questions the use of SEGRAs. So far, the molecular
mechanisms of GR-induced restriction of inflammation
are not completely understood and pose an interesting
field of investigation. In-depth knowledge of these mech-
anisms will elucidate whether GR ligands or SEGRAs are
potential therapeutics for inflammation, or whether they
could be dangerous because they might cause immunos-
timulation in certain inflammatory diseases. Here, we
want to stress that thorough studies are needed to unravel
the mechanistic details of the anti-inflammatory cascade
of GR, in an inflammation-specific way. Hence, the iden-
tification and further use of SEGRAs obviously hold a
brake to the full cascade. The identification of disease-
specific GR agonists will be necessary to reduce patient
suffering and decrease economic costs.
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